Jeffrey W Cooney
I see patients with a broad range of movement disorders, including Parkinson's disease, tremors, ataxia, dystonia, tics, and Huntington's disease. I employ deep brain stimulation (DBS) therapy for selected patients with Parkinson's disease, tremor, or dystonia, and use botulinum toxin injections for certain patients with dystonia, tremors, or tics. I work with an interdisciplinary team of physicians, therapists, and other healthcare providers, with the overall goal of helping to improve the lives of patients with complex neurological diseases.
Education and Training
- M.D., University of North Carolina - Chapel Hill, 2010
Selected Grants and Awards
- A Multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Pa
- Scalar Closed-Loop STN/GPi DBS Based on Evoked and Spontaneous Potentials
- Mitochondrial DNA damage as a blood-based biomarker of early Parkinson's disease
- PHASE 2A, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF BTRX-246040 IN PARKINSON'S DISEASE SUBJECTS WITH MOTOR FLUCTUATIONS ( PROTOCOL NEP-PD-201)
- Protecting Neurodevelopment in Latino Migrant Children by Reduced Exposure to Organophosphate Pesticides
- A Phase 2a, Double-Blind, Placebo-Controlled, Two-Part Study To Investigate the Safety And Efficacy Of Increasing Doses Of DNS-7801 In Parkinson's Disease (PD) Subjects With Motor Fluctuations
- Neuroderm- UBeyoNDU
- A MultiCtr,OL,dosageranging study in early,untreated or stably treated subjects with Parkinson's PD to determine the safety,tolerability and PK of inj ofSER-214administered subcu once a week for two weeks after 0-2 weeks of dose titration.